The diagnosis of Parkinson’s disease with dementia (PDD) or dementia with Lewy bodies (DLB) is based on an arbitary distinction between the time of onset of motor and cognitive symptoms. These syndromes share many neurobiological similarities, but there are also differences. Deposition of beta-amyloid protein is more marked and more closely related to cognitive impairment in DLB than PDD, possibly contributing to dementia at onset. The relatively more severe executive impairment in DLB than PDD may relate to the loss of frontohippocampal projections in DLB. Visual hallucinations and delusions associate with more abundant Lewy body pathology in temporal cortex in DLB. The differential involvement of pathology in the striatum may account for the differences in parkinsonism. Longitudinal studies with neuropathological and neurochemical evaluations will be essential to enable more robust comparisons and determine pathological substrates contributing to the differences in cognitive, motor, and psychiatric symptoms. (J Geriatr Psychiatry Neurol 2004; 17:137-145)
1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47:1113-1124.
2.
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol2003; 60:387-392.
3.
3. Burton EJ, McKeith IG, Burn DJ, Williams ED, O’Brien JT. Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain2004; 127(pt 4):791-800.
4.
4. Double KL, Halliday GM, McRitchie DA, Reid WG, Hely MA, Morris JG. Regional brain atrophy in idiopathic Parkinson’s disease and diffuse Lewy body disease. Dementia1996; 7:304-313.
5.
5. Harvey GT, Hughes J, McKeith IG, et al. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer’s disease: a pilot study. Psychol Med1999; 29:181-187.
6.
6. Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol2000; 47:718-728.
7.
7. Barber R, McKeith I, Ballard C, O’Brien J.Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. J Neurol Neurosurg Psychiatry2002; 72:406-407.
8.
8. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O’Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: an MRI study. Neurology2003; 61:1191-1195.
9.
9. Barber R, McKeith IG, Ballard C, Gholkar A, O’Brien JT. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer’s disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord2001; 12:198-205.
10.
10. Gomez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology1999; 53:2003-2009.
11.
11. Broe M, Shepherd CE, Milward EA, Halliday GM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol (Berl)2001; 101:616-624.
12.
12. Shepherd CE, McCann H, Thiel E, Halliday GM. Neurofilament-immunoreactive neurons in Alzheimer’s disease and dementia with Lewy bodies. Neurobiol Dis2002; 9:249-257.
13.
13. Harding AJ, Lakay B, Halliday GM. Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol2002; 51:125-128.
14.
14. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl)2001; 102:355-363.
15.
15. Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry2003; 74:852-856.
16.
16. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol2002; 59:102-112.
17.
17. Richard IH, Papka M, Rubio A, Kurlan R.Parkinson’s disease and dementia with Lewy bodies: one disease or two?Mov Disord2002; 17:1161-1165.
18.
18. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain2002; 125:391-403.
19.
19. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer’s disease. J Neuropathol Exp Neurol1996; 55:44-52.
20.
20. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol (Berl)2003; 106:83-88.
21.
21. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson’s disease. Mov Disord2003; 18:81-86.
22.
22. Jellinger KA, Seppi K, Wenning GK, Poewe W.Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm2002; 109:329-339.
23.
23. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain1999; 122(pt 8):1449-1468.
24.
24. O’Brien JT, Colloby SJ, Aarsland D, et al. Dopamine transporter loss visualised with PF-CIT SPECT in dementia with Lewy bodies. Arch Neurol In press.
25.
25. Ransmayrl G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med2001; 28:1523-1528.
26.
26. Halliday GM, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JG. Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease. J Clin Neurosci1996; 3:52-60.
27.
27. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol2002; 52:205-210.
28.
28. Duda JE. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord2004; 17(suppl 1):3-14.
29.
29. Piggott MA, Owens J, O’Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease. J Chem Neuroanat2003; 25:161-173.
30.
30. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer’s dementias. Ann Neurol2002; 51:767-771.
31.
31. Tiraboschi R, Hansen LA, Alford M, et al. Cholinergic dys-function in diseases with Lewy bodies. Neurology2000; 54:407-411.
32.
32. Ziabreva I, Ballard CG, Aarsland D, Larsen JP, Perry EK. Cortical and thalamic cholinergic activity in Lewy body disease in relation to dementia and parkinsonism. Paper presented at: 8th International Congress of Parkinson’s Disease and Movement Disorders; June 13-17, 2004; Rome, Italy.
33.
33. Lippa CF, Smith TW, Perry E.Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm1999; 106:525-535.
34.
34. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry1985; 48:413-421.
35.
35. Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience2000; 98:79-87.
36.
36. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R.Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases. J Neurochem1992; 58:529-541.
37.
37. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol2000; 48:868-876.
38.
38. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord1993; 7:69-79.
39.
39. Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsycho-pharmacology2004; 29:108-116.
40.
40. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science1997; 276:2045-2047.
41.
41. Hardy J.The relationship between Lewy body disease, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci2003; 991:167-170.
42.
42. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science2003; 302:841-841.
43.
43. Tsuang DW, Dalan AM, Eugenio CJ, et al. Familial dementia with Lewy bodies: a clinical and neuropathological study of 2 families. Arch Neurol2002; 59:1622-1630.
44.
44. Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, Halliday GM. Identification of families with cortical Lewy body disease. Am J Med Genet In press.
45.
45. Singleton AB, Wharton A, O’Brien KK, et al. Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord2002; 14:167-175.
46.
46. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson’s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics2002; 79:458-461.
48. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology2002; 59:1714-1720.
49.
49. Cormack F, Aarsland D, Ballard CG, Trovée MJ. Pentagon drawing and neuropsychological performance in dementia with Lewy bodies, Alzheimer’s disease, Parkinson’s disease and Parkinson’s disease with dementia. Int J Geriatr Psychiatry2004; 19:371-377.
50.
50. Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry1999; 156:1039-1045.
51.
51. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology1996; 47:1148-1152.
52.
52. Aarsland D, Ballard C, Larsen JP, McKeith I.A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry2001; 16:528-536.
53.
53. Boeve. Boeve F, Silber M, Ferman T. REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia With Lewy Bodies. J Geriatr Psychiatry Neurol2004; 17:146-157.
54.
54. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occur-rence of depression in Parkinson’s disease: a community-based study. Arch Neurol1996; 53:175-179.
55.
55. Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson’s disease. J Neuropsychiatry Clin Neurosci2001; 13:374-379.
56.
56. Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P.Motor and cognitive function in Lewy body dementia: comparison with Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry1997; 62:243-252.
57.
57. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord2003; 18:884-889.
58.
58. Ballard C, O’Brien J, Swann A, et al. One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord2000; 11:219-222.
59.
59. Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Neurology1996; 47:S146-S152.
60.
60. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E.Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ1992; 305:673-678.
61.
61. Aarsland D, Ballard CG, Larsen JP, McKeith IG, O’Brien J, Perry R.Marked neuroleptic sensitivity in dementia with Lewy bodies and Parkinson’s disease. Nord J Psychiatry2003; 57:94-94.
62.
62. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry2003; 18:988-993.
63.
63. Molloy S, O’Brien J, McKeith IG, Burn D.The motor response to levodopa (Ldopa) in dementia with Lewy bodies (DLB): a comparison to Parkinson’s disease (PD) with and without dementia. Paper presented at: 3rd International Workshop on Dementia With Lewy Bodies and Parkinson’s Disease Dementia (DLB/PDD); 2003; Newcastle Upon Tyne, United Kingdom.
64.
64. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology2003; 60:1586-1590.
65.
65. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in autopsy-confirmed prospectively studied patients with dementia with Lewy bodies (DLB). Am J Psychiatry2004; 161:843-849.
66.
66. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry2003; 74:1215-1220.
67.
67. Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y.Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord2004; 19:60-67.
68.
68. Horimoto Y, Matsumoto M, Nakazawa H, et al. Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol Sci2003; 216:105-108.
69.
69. Downes JJ, Priestley NM, Doran M, Ferran J, Ghadiali E, Cooper P.Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson’s disease. Behav Neurol1998; 11:173-183.
70.
70. Cahn-Weiner DA, Williams K, Grace J, Tremont G, Westervelt H, Stern RA. Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol2003; 16:85-92.
71.
71. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov Disord2003; 18(suppl 6):S72-S79.
72.
72. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry2002; 63:513-515.
73.
73. Rouleau I, Salmon DP, Butters N, et al. Quantitative and qualitative analyses of clock drawings in Alzheimer’s and Huntington’s disease. Brain Cogn. 1992; Jan; 18:70-87.
74.
74. Bourke J, Castleden CM, Stephen R, Dennis M.Short report: a comparison of clock and pentagon drawing in Alzheimer’s disease. Int J Geriatr Psychiatry1995; 10:703-705.
75.
75. Stern Y, Mayeux R, Sano M, et al. Predictors of disease course in patients with probable Alzheimer’s disease. Neurology1987; 37:1649-1653.
